ICCC
ICCC
NASDAQ · Biotechnology

Immucell Corp

$8.05
-0.42 (-4.96%)
As of May 16, 2:18 AM ET ·
Financial Highlights (FY 2026)
Revenue
30.44M
Net Income
-1,145,102
Gross Margin
41.4%
Profit Margin
-3.8%
Rev Growth
+14.2%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin -2.1% -1.9% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 30.44M 26.66M 25.83M 25.29M
Gross Profit 12.60M 11.04M 12.69M 12.42M
Operating Income -651,493 -513,525 1.23M 1.19M
Net Income -1,145,102 -902,602 1.23M 1.32M
Gross Margin 41.4% 41.4% 49.1% 49.1%
Operating Margin -2.1% -1.9% 4.8% 4.7%
Profit Margin -3.8% -3.6% 4.8% 5.2%
Rev Growth +14.2% +14.2% +0.8% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 10.07M 10.07M 3.09M 3.10M
Total Equity 29.94M 29.94M 31.72M 30.36M
D/E Ratio 0.34 0.34 0.10 0.10
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 2.22M 1.85M 1.46M 1.67M
Free Cash Flow 1.13M 847.0K